Fig. 2. Drug sensitivity profile of EGFR-TKI of EGFR-L747P mutation.

a EGFR gene mutations, EGFR exon 19 deletions, exon 21 L858R, and exon 19 L747P were introduced into Ba/F3 cells. EGFR mutant Ba/F3 cells were treated with gefitinib, erlotinib, afatinib, dacomitinib, and osimertinib. After 72 h of drug treatment, cell viability was measured using the CellTiter-Glo assay (n = 3). b Average IC₅₀ value of each Ba/F3 cell for EGFR-TKIs is shown, obtained using the CellTiter-Glo assay. Results are expressed as mean ± SD calculated from the 3 experimental replicates. IC₅₀ values were calculated using the CellTiter-Glo assay. c–e Suppression of phosphorylated EGFR in EGFR gene-transfected Ba/F3 cells by EGFR-TKI treatment. Cells were exposed to increasing concentrations of each inhibitor (10, 100, and 1000 nM) for 8 h and then immunoblotted for cell lysates to detect the indicated proteins.